SUBCONTRACT MODIFICATION Page 1 of 1
Exhibit 10.2
|
Page 1 of 1 |
|||||||||||||||||||||||||||
|
1. SUBCONTRACTOR SERVICE AGREEMENT NO.: |
2. EFFECTIVE DATE: |
3. MODIFICATION NUMBER: |
4. MODIFICATION DATE: |
||||||||||||||||||||||||
|
DPSC02-02257 |
5/12/2003 |
03 |
5/22/2003 |
||||||||||||||||||||||||
|
5. CONTRACTOR NAME AND ADDRESS: |
6. SUBCONTRACTOR NAME AND ADDRESS: |
||||||||||||||||||||||||||
|
DynPort Vaccine Company LLC 00 Xxxxxx Xxxxxxx Xxxxx Xxxxxxxxx, XX 00000 |
AVANT Immunotherapeutics, Inc. 000 Xxxxxx Xxxxxx Xxxxxxx, XX 00000-0000 |
||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
Representatives: |
Representatives: |
||||||||||||||||||||||||||
|
Contractual: Telephone: Technical: Telephone: |
Xx. Xxx Xxxxxx 000-000-0000 Xx. Xxxxxxx Xxxxx 000-000-0000 |
Contractual: Telephone: Technical: Telephone: |
Xx. Xxxx Xxxxxx 000-000-0000 Xx. Xxxxx Xxxxxxx 781-433-0771 |
||||||||||||||||||||||||
|
7a. SUBCONTRACT MODIFICATION VALUE: |
|
8a. REFERENCE DOCUMENTS: |
|||||||||||||||||||||||||
|
|
|
Prime Contract No. DAMD17-98-C-8024 |
|||||||||||||||||||||||||
|
|
|
Current Value |
|
Increase/Decrease |
|
Total Value |
|
|
|
||||||||||||||||||
|
Labor |
|
$ |
2,308,450.62 |
|
$ |
1,030,911.36 |
|
$ |
3,339,361.98 |
|
8b. DPAS RATING: |
|
|||||||||||||||
|
Other Direct Costs |
|
$ |
158,877.00 |
|
$ |
223,480.36 |
|
$ |
382,357.36 |
|
DO-C9 |
|
|||||||||||||||
|
Total |
|
$ |
2,467,327.62 |
|
$ |
1,254,391.72 |
|
$ |
3,721,719.34 |
|
|
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
|
7b. REVISED SUBCONTRACT AUTHORIZED FUNDED VALUE:
|
|
|
|
||||||||||||||||||||||||
|
|
|
Prior Funded Value |
|
Increase/Decrease |
|
Revised Funded Value |
|
|
|||||||||||||||||||
|
9a. AGREEMENT PERIOD OF PERFORMANCE: |
|||||||||||||||||||||||||||
|
|
|
$ |
2,467,327.62 |
|
$ |
1,254,391.72 |
|
$ |
3,721,719.34 |
|
FROM: 12/31/2002 |
TO: 8/30/2004 |
|||||||||||||||
|
|
|
|
|
|
|
|
|
9b. AGREEMENT TYPE: |
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
Time & Materials |
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
9c. MODIFICATION PERIOD OF PERFORMANCE: |
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
FROM: 5/12/2003 |
TO: 8/30/2004 |
||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||||||
|
10. This is a |
o ADMINISTRATIVE CHANGE |
ý CHANGE ORDER |
o SUPPLEMENTAL AGREEMENT |
||||||||||||||||||||||||
|
11. DESCRIPTION OF MODIFICATION: |
|||||||||||||||||||||||||||
|
Modification No. 3 to Subcontractor Service Agreement No. DPSC02-02257 is hereby issued to: |
|||||||||||||||||||||||||||
|
1. Attachment A, Statement of Work, is incorporated herein. |
|||||||||||||||||||||||||||
|
2. Attachment B, Price Schedule, is incorporated herein. |
|||||||||||||||||||||||||||
|
3. Attachment C, Performance Schedule, is incorporated herein. |
|||||||||||||||||||||||||||
|
4. Charges incurred under and authorized by this Subcontract Modification shall be charged against the following Contract Work Breakdown Structure (CWBS) numbers as appropriate, which shall be referenced on all project invoices and documentation: |
|||||||||||||||||||||||||||
|
CWBS No. C.5.9.3.1: Establish Mouse and Rabbit Models for Assessing Immunogenicity of Live Bacterial Vector Vaccines |
|||||||||||||||||||||||||||
|
CWBS No. C.5.9.3.2: Establish Mouse Models for Immunogenicity Ttesting of Antigen+Alhydrogel |
|||||||||||||||||||||||||||
|
CWBS No. C.5.9.3.3: Screen and Select Optimal Live Bacterial Vector Vaccine Candidates |
|||||||||||||||||||||||||||
|
CWBS No. C.5.9.3.4: Demonstrate the Immunogenicity of Live Bacterial Vector Vaccines in Mice |
|||||||||||||||||||||||||||
|
CWBS No. C.5.9.3.5: Vaccination Studies in New Zealand White Rabbits |
|||||||||||||||||||||||||||
|
CWBS No. C.5.9.3.6: Project Management |
|||||||||||||||||||||||||||
|
5. All other terms and conditions of Subcontractor Service Agreement No. DPSC02-02257 remain unchanged and in full force and effect. |
|||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||
|
Except as provided herein, all terms and conditions of the document referenced in Block No. 1 remain unchanged and in full force and effect. |
|||||||||||||||||||||||||||
|
12. SUBCONTRACTOR: |
|
oIS NOT |
ýIS |
REQUIRED TO SIGN THIS DOCUMENT AND RETURN TWO COPIES TO THE ISSUING OFFICE. |
|||||||||||||||||||||||
|
13. SUBCONTRACTOR: AVANT Immunotherapeutics, Inc. |
14. DynPort Vaccine Company LLC: |
||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
|
/s/ Xxxxx X. Xxxxxx May 23, 2003 |
|
|
/s/ Xxx Xxxxxx May 27, 2003 |
|
||||||||||||||||||||||
|
|
(Signature of Authorized Company Representative) & Date |
|
|
(Signature of Authorized Company Representative) & Date |
|
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
15. NAME & TITLE OF AUTHORIZED COMPANY REPRESENTATIVE: |
16. NAME & TITLE OF AUTHORIZED COMPANY REPRESENTATIVE: |
||||||||||||||||||||||||||
|
(Type or Print) |
|
||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
|
Xxxxx X. Xxxxxx, Senior Vice President and Chief Financial Officer |
|
Xxx Xxxxxx, Senior Manager, Subcontracts |
||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
1
